In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

William Looney

Executive Editor

New York, NY
Advertisement
Set Alert for Articles By William Looney

Latest From William Looney

Personalized Medicine: A Patient Primer On Best Practice

Personalized medicine is focused on meeting patients’ needs, but it also has the potential to transform the delivery and financing of health care. In Vivo probes the path toward meeting both goals in an in-depth nterview with Eleanor Perfetto, SVP for strategic initiatives at the National Health Council, the DC-based patient advocacy organization whose members include groups representing 133 million patients nationwide.

Personalized Medicine Leadership

Drug Value: It’s Personal, Patients Say

In a series of meetings and workshops over the past 18 months, the National Health Council has developed a platform that consolidates the patient community’s perspective on how to assess value in choosing among alternative therapies in biopharmaceuticals and other key health care interventions.

BioPharmaceutical

Frost On Opportunities In Quality-Of-Life Therapies

Opko Health has created a dedicated R&D team to explore solutions for conditions that impair patients' quality of life.

BioPharmaceutical

The Frost Factor: An M&A Leader's Standout Strategy For Opko Health

With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model.

Business Strategies Deals

Frost On The Art Of The Deal

What Phillip Frost looks for when evaluating potential strategic partners.

BioPharmaceutical

Behind The Blockbuster: Investors Sound Off On Biogen's Future With Spinraza

Entering 2017 with freshly approved Spinraza and new CEO Michel Vounatsos, Biogen still faces challenges and uncertainty. A poll of investors highlights expectations for the company.

Business Strategies Commercial
See All
Advertisement
UsernamePublicRestriction

Register